Order of Three Systems from Mälarsjukhuset in Eskilstuna

Press release 2014-07-9

        Print
| Source: C-Rad AB

C-RAD signed a contract for in total three C-RAD systems with Mälarsjukhuset Eskilstuna. The order contains two Catalyst™ and one Sentinel 4DCT™ System.

The Catalyst will be delivered with the complete software configuration containing modules for Respiratory gating, Patient Setup and Positioning and Motion Monitoring as well as respective interfaces to the existing CT and linear accelerators. The procurement was through a public tender, specifically for surface tracking devices.

The radiotherapy center in Eskilstuna is equipped with two Elekta linear accelerators and a GE CT. The installation of the Sentinel 4DCT System will take place after the summer. The installation at the Catalystsystems will follow.

The Catalyst and Sentinel system offer the required technology to perform high end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

 

Tim Thurn, CEO, C-RAD AB:

“I am pleased to announce that Mälarsjukhuset Eskilstuna has decided for the C-RAD technology. This project underlines the strong interest from customers and the market potential for the C-RAD systems.”

 

 

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.

 

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

 

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).